A Phase 1 Dose-escalation Study of PSMA ADC in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer.

Trial Profile

A Phase 1 Dose-escalation Study of PSMA ADC in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2013

At a glance

  • Drugs PSMA ADC (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Progenics Pharmaceuticals
  • Most Recent Events

    • 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 14 Feb 2013 Updated results were presented at the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium according to a Progenics Pharmaceutical media release. Results were also briefly summarised in the media release.
    • 28 Sep 2012 Results will be presented at the 2012 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics according to a Progenics Pharmaceuticals media release. Results were also briefly summarised in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top